Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Sep 10;21(1):48-50.
doi: 10.1177/1535759720951791. eCollection 2021 Jan-Feb.

Is On-Demand Dynorphin Destined to Be in Demand to Decrease Seizures?

Catherine A Christian-Hinman
Comment

Is On-Demand Dynorphin Destined to Be in Demand to Decrease Seizures?

Catherine A Christian-Hinman. Epilepsy Curr. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Asadi-Pooya AA, Stewart GR, Abrams DJ, Sharan A. Prevalence and incidence of drug-resistant mesial temporal lobe epilepsy in the united states. World Neurosurg. 2017;99:662–666. doi:10.1016/j.wneu.2016.12.074 - PubMed
    1. Faught E, Duh MS, Weiner JR, Guérin A, Cunnington MC. Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM Study. Neurology. 2008;71(20):1572–1578. doi:10.1212/01.wnl.0000319693.10338.b9 - PubMed
    1. Kovac S, Walker MC. Neuropeptides in epilepsy. Neuropeptides. 2013;47(6):467–475. doi:10.1016/j.npep.2013.10.015 - PubMed
    1. Noè F, Pool AH, Nissinen J, et al. Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain. 2008;131(pt 6):1506–1515. doi:10.1093/brain/awn079 - PubMed
    1. Agostinho AS, Mietzsch M, Zangrandi L., et al. Dynorphin-based “release on demand” gene therapy for drug-resistant temporal lobe epilepsy. EMBO Mol Med. 2019;11(10):e9963 doi:10.15252/emmm.201809963 (2019) - PMC - PubMed

LinkOut - more resources